Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine + lenalidomide in relapsed or refractory T-cell lymphoma (Phase II)
KCT0012239Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine and lenalidomide in non-Hodgkin lymphoma, T-cell, sponsored by Boryung. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
azacitidinelenalidomide
03
Conditions
non-Hodgkin lymphoma, T-cell
Beyond the preview
Go deeper on KCT0012239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012239.